GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of ...
GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits ...
GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion.
The agreement frees the British pharma giant from litigating 93% of the state court cases it faced in the U.S.
The deal settles 80,000 US court cases related to allegations that Zantac was contaminated with a suspected carcinogen.
Pharmaceutical giant GSK will pay up to £1.7billion to settle thousands of legal cases that claimed its heartburn drug Zantac ...
Pharmaceutical giant GlaxoSmithKline (GSK) has agreed to pay up to $2.2 billion to settle most of lawsuits filed in U.S.
Zantac was pulled from shelves in 2019 amid panic that a key ingredient - ranitidine - could cause cancer, plunging GSK and ...
GSK’s American depositary receipts rose as much as 9.9% in New York after the agreement was announced. GSK is among a number of companies that made and sold versions of Zantac, and investor ...